You are here:
SYMPOSIUM OVERVIEW: SYMPOSIUM ON APPLICATION OF PHARMACOKINETICS IN DEVELOPMENTAL TOXICOLOGY RISK ASSESSMENTS
Citation:
Kavlock, R., D. Mattison, H. Nau, J. Young, AND J. Gabrielsson. SYMPOSIUM OVERVIEW: SYMPOSIUM ON APPLICATION OF PHARMACOKINETICS IN DEVELOPMENTAL TOXICOLOGY RISK ASSESSMENTS. U.S. Environmental Protection Agency, Washington, D.C., EPA/600/J-91/124 (NTIS PB91211474), 1991.
Description:
A symposium entitled "Application of Pharmacokinetics in Developmental Toxicity Risk Assessments" was held at the 29th Annual Meeting of the Society of Toxicology (SOT) in Miami Beach, Florida. t was sponsored by the Reproductive and Developmental Specialty Section of SOT to address the current state of knowledge relating to the use of physiological and metabolic information in reducing the uncertainties inherent in the presently practiced procedures for extrapolating animal toxicology data to the human situation. he goal of this symposium is to communicate where we are in the process of moving pharmacokinetic data from a research mode to an application mode. he first speaker, Dr. Donald R. Mattison of the University of Arkansas, discussed physiological adaptations required for successful pregnancy and how these might impact on the manifestation of developmental toxicity across species. r. Heinz Nau of the Free University of Berlin discussed the use of pharmacokinetics for the interpretation of teratogenicity studies in regard to interspecies extrapolation and structure-activity relationships, and how this information might be used to modify testing protocols to more accurately reflect human exposure patterns. r. John F. Young of the National Center for Toxicological Research spoke on the use of multiple correlation procedures to determine which pharmacokinetic parameters are most appropriate as integrated internal dose estimates for quantitative dose-response modelling. r. Robert J. Kavlock of the U.S. Environmental Protection Agency next discussed rodent whole embryo culture, and how it presents advantages and disadvantages for assessment of pharmacokinetic factors in teratogenesis. inally, Dr. Johan Gabrielson of the University of Uppsala (Sweden) who was on sabbatical at the University of California, San Francisco, introduced the concept of physiologically based pharmacokinetic modelling and how it can e applied to extrapolate data between species.